# A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

> **NCT05651932** · PHASE1 · RECRUITING · sponsor: **K36 Therapeutics, Inc.** · enrollment: 125 (estimated)

## Conditions studied

- Multiple Myeloma
- Myeloma
- Myeloma Multiple

## Interventions

- **DRUG:** Cohort A1 & A2: KTX-1001
- **DRUG:** Cohort B1 & B2: KTX-1001+Mezigdomide
- **DRUG:** Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- **DRUG:** Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)

## Key facts

- **NCT ID:** NCT05651932
- **Lead sponsor:** K36 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-22
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05651932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05651932, "A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05651932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*